Antibacterial Activity and Acute Toxicity Testing of Biosynthesized Silver Nanoparticles against Methicilin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa
ABSTRACT Antibacterial activity of biosynthesized silver nanoparticles was studied using the macrobroth dilution technique. The silver nanoparticles was significantly active (p > 0.05) against the test organisms at an extract concentration of 75 µg/ml. Concentrations ≤ 50 µg/ml were not as effective as the colony forming units at this concentration, 1.61 × 106 for methicillin-resistant Staphylococcus aureus and concentrations ≤ 25 µg/ml 1.45 × 106 for Pseudomonas aeruginosa respectively, were about the same range as the colony forming units of the controls. The silver nanoparticles inhibited Methicillin-Resistant S. aureus more (MIC of 75 µg/ml and MBC of 100 µg/ml) than they inhibited P. aeruginosa (both MIC and MBC was 100 µg/ml). The LD50 of the synthesized silver nanoparticles after oral administration was seen to be greater than 5000 mg/kg body weight and is therefore thought to be safe. This study supports the use of silver nanoparticles as therapeutic agents..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 04. Juni Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Olobayotan, Ifeyomi Wilfred [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2021.06.02.446742 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI031902731 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI031902731 | ||
| 003 | DE-627 | ||
| 005 | 20230429081500.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210604s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.06.02.446742 |2 doi | |
| 035 | |a (DE-627)XBI031902731 | ||
| 035 | |a (biorXiv)10.1101/2021.06.02.446742 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Olobayotan, Ifeyomi Wilfred |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibacterial Activity and Acute Toxicity Testing of Biosynthesized Silver Nanoparticles against Methicilin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Antibacterial activity of biosynthesized silver nanoparticles was studied using the macrobroth dilution technique. The silver nanoparticles was significantly active (p > 0.05) against the test organisms at an extract concentration of 75 µg/ml. Concentrations ≤ 50 µg/ml were not as effective as the colony forming units at this concentration, 1.61 × 106 for methicillin-resistant Staphylococcus aureus and concentrations ≤ 25 µg/ml 1.45 × 106 for Pseudomonas aeruginosa respectively, were about the same range as the colony forming units of the controls. The silver nanoparticles inhibited Methicillin-Resistant S. aureus more (MIC of 75 µg/ml and MBC of 100 µg/ml) than they inhibited P. aeruginosa (both MIC and MBC was 100 µg/ml). The LD50 of the synthesized silver nanoparticles after oral administration was seen to be greater than 5000 mg/kg body weight and is therefore thought to be safe. This study supports the use of silver nanoparticles as therapeutic agents. | ||
| 700 | 1 | |a Akin-Osanaiye, Bukola Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Onuh, Olukemi A. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 04. Juni |
| 773 | 1 | 8 | |g year:2021 |g day:04 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.06.02.446742 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 04 |c 06 | ||
| 953 | |2 045F |a 570 | ||